Amanda Jones, PharmD

  • 1Article
  • 48.8KReads
  • 2022Active
  • 6Collaborators
  • 115Citations

About

Amanda Jones, PharmD is affiliated with Axsome Therapeutics, Inc, New York, New York. Amanda Jones has contributed 1 peer-reviewed article published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders in 2022. Their work focuses on Depression (MDD).

Publications

JCP
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in MDD
Original Research

Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in MDD

May 30, 2022

Altered glutamatergic neurotransmission has been implicated in the pathogenesis of depression. This phase 3 trial evaluated the efficacy and safety of AXS-05 (dextromethorphan-bupropion) in the treatment of major depressive...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe